| Hazard Information | Back Directory | [Uses]
Cevipabulin fumarate (TTI-237 fumarate) is an oral, microtubule-active, antitumor compound and inhibits the binding of [3H]NSC 49842 to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line[1][2]. | [in vivo]
Cevipabulin (TTI-2370)( 5, 10, 15, and 20 mg/kg, every 4 days for 4 cycles, in mice) is active by i.v. and p.o. administration against human tumor xenografts, showing dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg[1]. | Animal Model: | Athymic nu/nu female mice implanted s.c. in the flank with 1×107 LoVo human colon adenocarcinoma cells[1]. | | Dosage: | 5, 10, 15, and 20 mg/kg | | Administration: | I.V. injection every 4 days for 4 cycles. | | Result: | The compound showed dose-dependent effects, with good antitumor activity at 20 and 15 mg/kg. |
| Animal Model: | Athymic nu/nu female mice implanted s.c. in the flank with 1×106 U87-MG human glioblastoma cells[1]. | | Dosage: | 25 mg/kg. | | Administration: | P.O. or I.V. on days 0, 7, 14. | | Result: | The compound was active by p.o. or i.v. administration against human tumor xenografts. |
| [storage]
Store at -20°C | [References]
[1] Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68(7):2292-300. DOI:10.1158/0008-5472.CAN-07-1420
[2] Beyer CF, et al. The microtubule-active antitumor compound TTI-237 has both DB01229-like and Leurocristine-like properties. Cancer Chemother Pharmacol. 2009 Sep;64(4):681-9. DOI:10.1007/s00280-008-0916-2 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|